Get the Daily Brief
Latest Biotech News
Regulatory turbulence and outcomes for small biotechs and telehealth
A STAT+ report described how Kezar Life Sciences closed its doors after an FDA meeting on trial design was canceled months after the company had reached an agreement—leaving no clear path forward....
Amgen pushes Tepezza competitive defenses with injectable Phase 3 data
Amgen reported that an injectable version of Tepezza (teprotumumab-trbw) succeeded in a Phase 3 study for thyroid eye disease, setting up direct competition with Viridian Therapeutics’ recently...
Oncology genomics debate heats up: push for routine whole-genome sequencing
Dutch researchers argued in Nature Medicine that whole-genome sequencing (WGS) should be incorporated into routine cancer care, using real-world data from 888 patients treated at the Netherlands...
Multi-disease liquid biopsy: UCLA’s cfDNA methylation MethylScan
UCLA scientists unveiled MethylScan, a low-cost blood test aimed at simultaneously detecting multiple cancers and non-malignant conditions using cfDNA methylome profiling. Early studies in more...
Genomics and immunology infrastructure: ASHOP integrates hematologic ‘omics’
St. Jude Children’s Research Hospital, the American Society of Hematology (ASH), and Munich Leukemia Laboratory launched the ASH HematOmics Program (ASHOP), described as an integrative data...
Trial design and digital compliance: BMS adopts Faro AI for protocols
Bristol Myers Squibb will use artificial intelligence to develop clinical trial protocols in partnership with Faro Health, marking the drugmaker’s second AI-focused deal in as many months. The...
Biotech funding momentum: Syneron peptides funding and Stipple launches
Syneron Bio raised $150 million in a Series B to develop a peptide drug class, extending investment momentum from its prior $100 million round. The new capital supports program development and...
Drug development strategy shift: charged molecular glue discovery via targeted degron display
A Nature Chemical Biology study reported a discovery strategy for charged molecular glues enabled by targeted degron display. The work describes a method to identify small molecules that promote...
M&A: Neurocrine’s $2.9B move into Prader-Willi (Soleno buyout)
Neurocrine Biosciences agreed to acquire Soleno Therapeutics in a $2.9 billion deal, picking up Soleno’s Prader-Willi syndrome therapy Vykat (setmelanotide for hyperphagia). Neurocrine will pay...
Regulatory strategy: FDA proposes optional risk-based expedited IND pathway; Takeda drops Denali program
The FDA is floating a new optional, risk-based expedited Investigational New Drug pathway in its FY2027 budget request, intended to speed experimental drugs into early human testing. The proposal...
Clinical pipeline competition in ophthalmology: Tepezza injectable Phase 3 data
Amgen reported success for an injectable formulation of Tepezza (teprotumumab) in a Phase 3 study for thyroid eye disease, setting up an escalation in competition. The company’s move comes as...
Funding: Syneron Bio raises $150M Series B for peptide platform; Syneron’s prior round cited
Syneron Bio raised $150 million in a Series B round to develop a peptide drug class designed to borrow some of the properties of biologics. The company said the financing will support development...
Corporate AI for trials: BMS partners with Faro Health for AI-driven protocol design
Bristol Myers Squibb is partnering with Faro Health to use AI agents for clinical trial protocol design, drafting, validation and optimization. Faro’s technology structures narrative protocol...
Oncology science: Tumor succinate metabolite reprograms bladder muscle to create metastatic vessel niches
Researchers from Sun Yat-Sen University reported a signaling–metabolic circuit that lets bladder tumors co-opt the local muscle microenvironment to generate metastatic blood-vessel niches. The...
Oncology science: Cold plasma-activated water shows anti-tumor effects in breast cancer preclinical models
Preclinical mouse data suggest cold plasma-activated water may inhibit breast cancer tumor growth. Researchers reported in a study on cold plasma-activated water’s effects against MCF7 breast...
Oncology science: Charged molecular glues via targeted degron display (Nature Chemical Biology)
A Nature Chemical Biology study reported a strategy to discover charged molecular glues enabled through targeted degron display. Molecular glues are small molecules that promote new...
Oncology therapeutics: Quizartinib plus omacetaxine shows promise in AML Phase 2
A Phase 2 trial in acute myeloid leukemia reported encouraging results for a combination of quizartinib and omacetaxine mepesuccinate. The study, published in Nature Communications in 2026,...
Platform/Diagnostics: Whole-body MRI diffusion predicts ovarian cancer outcomes after neoadjuvant chemotherapy
A study in the British Journal of Cancer reported that whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes for advanced ovarian cancer following neoadjuvant chemotherapy....
Neurocrine expands rare-disease footprint via Soleno acquisition
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion, adding Soleno’s Prader-Willi syndrome medicine Vykat to its portfolio and deepening its focus on rare diseases. The deal...
Takeda unwinds Denali collaboration amid restructuring
Takeda ended an eight-year partnership with Denali, returning full rights to Denali’s DNL593 ahead of the program’s Phase 1 steps. The termination arrives as Takeda continues restructuring, which...